Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01499290
Other study ID # D4280C00001
Secondary ID 2011-003893-97
Status Completed
Phase Phase 3
First received December 19, 2011
Last updated August 31, 2017
Start date March 2012
Est. completion date April 2014

Study information

Verified date August 2017
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.


Description:

A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults


Other known NCT identifiers
  • NCT01500239

Recruitment information / eligibility

Status Completed
Enrollment 493
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- 18 to 90 years of age inclusive

- Female patient is authorized to participate if at least one of the following criteria are met:

1. Surgical sterilization

2. Age =50 years and postmenopausal as defined by amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments

3. Age <50 years and postmenopausal as defined by documented LH and FSH levels in the postmenopausal range PLUS amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments

4. Patient has a negative serum pregnancy test (serum ß-human chorionic gonadotropin [ß-hCG]) within 1 day prior to study entry, and agrees to use highly effective contraception methods during treatment and for at least 7 days after last dose of IV study therapy

- Intraoperative/postoperative enrollment with confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis

- Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory response; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections

Exclusion Criteria:

- Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious

- Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation

- Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis

- Patient is considered unlikely to survive the 6 to 8 week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CAZ-AVI
Ceftazidime 2000 mg and 500 mg of avibactam
Metronidazole
500 mg of Metronidazole
Meropenem
1 gram of Meropenem

Locations

Country Name City State
Argentina Research Site Córdoba
Argentina Research Site Rosario
Bulgaria Research Site Ruse
Bulgaria Research Site Varna
Croatia Research Site Zagreb
Czechia Research Site Decin
Czechia Research Site Hradec Kralove
Czechia Research Site Jihlava
Czechia Research Site Olomouc
Czechia Research Site Praha 10
Czechia Research Site Praha 5
Czechia Research Site Teplice
Hungary Research Site Budapest
Hungary Research Site Székesfehérvár
India Research Site Bangalore
India Research Site Pune
India Research Site Trivandrum
India Research Site Vadodara
Israel Research Site Hadera
Israel Research Site Haifa
Latvia Research Site Riga
Malaysia Research Site Alor Setar
Mexico Research Site Durango
Mexico Research Site Guadalajara, Jalisco
Mexico Research Site Mexico City
Netherlands Research Site Enschede
Netherlands Research Site s-Hertogenbosch
Peru Research Site Arequipa
Peru Research Site Cercardo de Lima
Peru Research Site Lima
Peru Research Site Trujillo
Romania Research Site Cluj-Napoca
Romania Research Site Iasi
Russian Federation Research Site Kemerovo
Russian Federation Research Site Moscow
Russian Federation Research Site Saratov
Russian Federation Research Site Vsevolozhsk
South Africa Research Site Pretoria
Spain Research Site Alcorcón
Spain Research Site Elche
Spain Research Site Sabadell(Barcelona)
Taiwan Research Site Kaohsiung
Taiwan Research Site Taichung
Taiwan Research Site Tainan
Taiwan Research Site Taipei
Thailand Research Site Bangkok
Thailand Research Site Khon Kaen
Thailand Research Site Phisanulok
Ukraine Research Site Dnipropetrovsk
Ukraine Research Site Ivano-Frankivsk
Ukraine Research Site Kharkov
Ukraine Research Site Kyiv
Ukraine Research Site Zaporizhzhya
United States Research Site Chula Vista California
United States Research Site Saint Louis Missouri
United States Research Site San Diego California
United States Research Site Somers Point New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Pfizer Forest Laboratories

Countries where clinical trial is conducted

United States,  Argentina,  Bulgaria,  Croatia,  Czechia,  Hungary,  India,  Israel,  Latvia,  Malaysia,  Mexico,  Netherlands,  Peru,  Romania,  Russian Federation,  South Africa,  Spain,  Taiwan,  Thailand,  Ukraine, 

References & Publications (1)

Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA). The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention is necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, death where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA. TOC: 28 to 35 days after start of study drug
Primary Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]). The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. TOC: 28 to 35 days after start of study drug
Primary Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]). The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. TOC: 28 to 35 days after start of study drug
Secondary Clinical Cure at TOC in the Microbiologically Evaluable Analysis Set The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. TOC: 28 to 35 days after start of study drug
Secondary Clinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. TOC: 28 to 35 days after start of study drug
Secondary Clinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT) Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU: 42 to 49 days after start of study drug
Secondary Per-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set Microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to a surgical review panel (SRP) assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence). EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU 42 to 49 days after start of study drug
Secondary Per-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set. The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. TOC: 28 to 35 days after start of study drug.
Secondary Clinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Test of Cure: 28 to 35 days after start of study drug
Secondary Favorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. TOC: 28 to 35 days after start of study drug
Secondary Per-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set Microbiological responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence). Test of Cure: 28 to 35 days after start of study drug
Secondary Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry Time to first defervescence was calculated for patients with a fever (>38ºC) at baseline. Defervescence (=37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Test of Cure: 1 to 14 days after start of study drug
Secondary Plasma Concentrations for Ceftazidime and Avibactam Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug
See also
  Status Clinical Trial Phase
Recruiting NCT05905055 - P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales Phase 3
Completed NCT03293485 - Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) Phase 3
Recruiting NCT05148702 - EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection. Phase 3
Completed NCT04927312 - Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection Phase 3
Completed NCT00929643 - Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections N/A
Completed NCT01147640 - Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections Phase 2
Completed NCT01726023 - Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Phase 3
Completed NCT01644643 - Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens Phase 3
Withdrawn NCT01602874 - Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia Phase 3
Completed NCT01265784 - Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections Phase 2
Withdrawn NCT00914888 - Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia Phase 3
Completed NCT00157898 - A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED) Phase 4
Recruiting NCT05733104 - A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
Completed NCT01445678 - Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections Phase 3
Completed NCT02739997 - Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013) Phase 3
Completed NCT03329092 - A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. Phase 3
Completed NCT03217136 - MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) Phase 2
Completed NCT01500239 - A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections Phase 3